Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 25, 2026
CZR vs DKNG: Contrasting Paths in the U.S. Gaming Sector

CZR vs DKNG: Contrasting Paths in the U.S. Gaming Sector

Key Takeaways

  • CZR has outperformed in recent months with a strong year-to-date gain, while DKNG has fallen sharply and trades near its 52-week low.
  • The two companies sit at opposite ends of the gaming spectrum: Caesars is a land-based casino and hospitality operator, while DraftKings is a digital-first sportsbook and iGaming platform.
  • DraftKings carries a significantly larger market capitalization despite its smaller physical footprint, reflecting its faster revenue growth profile.
  • Caesars is navigating a proposed acquisition by Fertitta Entertainment, whereas DraftKings is contending with rising competition from prediction markets.
  • Wall Street consensus is more constructive on DraftKings (average "Buy" rating), while Caesars carries a "Hold" rating.
  • Caesars carries a substantial debt load, while DraftKings faces ongoing regulatory uncertainty and headline-driven volatility.

Setting the Context for CZR and DKNG

Investors evaluating CZR and DKNG are considering two distinct ways the legalized gaming theme is playing out in the United States. Caesars Entertainment reflects the traditional, asset-intensive casino and hospitality approach, whereas DraftKings represents the asset-light, mobile-oriented sports betting and online gaming space. This comparison stands out now because the stocks have been moving in different directions, which may help traders assess relative value and positioning. Those seeking more stability and physical assets might lean toward Caesars, while those prioritizing growth could focus on DraftKings' digital expansion.

CZR's Business and Recent Results

Caesars Entertainment (CZR) ranks among the largest casino operators in the country, with about 50 domestic properties under brands such as Caesars, Harrah's, Horseshoe, and Eldorado. Its operations include Las Vegas resorts, regional casinos, and a growing digital side that covers iGaming and sports betting. The stock has held up relatively well lately, posting a solid year-to-date advance and sitting toward the higher end of its 52-week range after earlier lows.

Recent developments include record revenue and adjusted EBITDA in the Digital segment, with online casino revenue rising at a double-digit rate. Governance news surfaced with the resignation of two directors, and the company is moving forward with the proposed Fertitta Entertainment acquisition at roughly $31 per share in cash. At the same time, investors are monitoring the sizable debt position and softer trends in Las Vegas and regional gaming against the digital gains. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

DKNG's Position and Recent Performance

DraftKings (DKNG) focuses on digital sports entertainment and gaming, primarily through its online sportsbook, iGaming products, and daily fantasy sports. It follows an asset-light model with minimal real estate and generates revenue from online wagering in multiple states. Performance has been weaker, with the stock declining notably over the past year and trading near its 52-week low, well below prior peaks.

Much of the pressure stems from the growth of prediction markets, where platforms like Kalshi and Polymarket have taken significant volume. DraftKings introduced its own exchange, DKeX, but its share of that market remains limited so far. Management points to solid underlying growth, including year-over-year increases in sportsbook handle and a goal of about $1 billion in adjusted EBITDA this year. Regulatory questions and media attention have nonetheless added volatility.

Head-to-Head Business and Market Comparison

The core difference lies in their models. Caesars operates with heavy capital tied to physical properties, leaving it more exposed to tourism patterns, regional trends, and its large debt obligations. DraftKings runs a lighter digital platform where success hinges on user growth, state-by-state legalization, and margin improvement, which makes it more sensitive to competition and regulatory changes.

Recent price action has favored Caesars, which advanced while DraftKings retreated. Valuation and analyst views add nuance, though. DraftKings commands a larger market capitalization and holds a consensus "Buy" rating, based on expectations for ongoing revenue and earnings growth. Caesars carries a "Hold" rating as the market weighs the acquisition, high leverage, and mixed operating results. Risk factors differ as well: Caesars contends with balance-sheet and deal-related issues, while DraftKings faces uncertainty around prediction markets and associated headlines. This sets up a contrast between current price resilience and longer-term growth prospects.

AI-Based Assessment of the Pair

From what I see, Tickeron's AI would likely take a measured stance. Caesars shows firmer trend consistency and stability right now, backed by its price recovery and the concrete support of a pending acquisition price. DraftKings benefits from stronger long-term growth expectations and analyst support but has weaker recent momentum. A trend-focused AI approach would therefore tend to favor the steadier path of CZR in the present setting, while noting that DKNG's fundamentals might allow a rebound with better regulatory clarity. This remains a probabilistic view rather than a firm forecast.

Exploring Systematic Trading Approaches

In my research process, I often review Tickeron’s Trending AI Robots to identify automated strategies that align with current market conditions. The platform curates top-performing bots from hundreds available, each with its own style, timeframe, and performance data. This helps narrow options to those best suited to prevailing trends without manual review of the full set.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: CZR, DKNG

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


CZR in upward trend: price may jump up because it broke its lower Bollinger Band on September 22, 2026

CZR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 38 of 48 cases where CZR's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 79%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 69 cases where CZR's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 65%.

Following a +0.10% 3-day Advance, the price is estimated to grow further. Considering data from situations where CZR advanced for three days, in 200 of 283 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on CZR as a result. In 74 of 101 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.

The Moving Average Convergence Divergence Histogram (MACD) for CZR turned negative on September 23, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 52 similar instances when the indicator turned negative. In 37 of the 52 cases the stock turned lower in the days that followed. This puts the odds of success at 71%.

The 10-day moving average for CZR crossed bearishly below the 50-day moving average on August 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 69%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CZR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 47 (best 1 - 100 worst), indicating steady price growth. CZR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 66 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.789) is normal, around the industry mean (25.546). P/E Ratio (10.418) is within average values for comparable stocks, (67.489). CZR's Projected Growth (PEG Ratio) (4.468) is very high in comparison to the industry average of (0.790). Dividend Yield (0.000) settles around the average of (0.012) among similar stocks. P/S Ratio (0.522) is also within normal values, averaging (1.049).

The Tickeron PE Growth Rating for this company is 85 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CZR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.

Notable companies

The most notable companies in this group are Las Vegas Sands Corp (NYSE:LVS), MGM Resorts International (NYSE:MGM), Wynn Resorts Limited (NASDAQ:WYNN), Melco Resorts & Entertainment Limited (NASDAQ:MLCO).

Industry description

The industry includes companies that operate and manage one or more of the following: lodging facilities (e.g. hotels and motels), resorts (e.g. ski resorts), spas, cruise ships and timeshare facilities. Marriott International, Inc., Carnival Corporation, Hilton Worldwide Holdings Inc. and Royal Caribbean Cruises Ltd. are some of the biggest names in this industry.

Market Cap

The average market capitalization across the Hotels/Resorts/Cruiselines Industry is 4.45B. The market cap for tickers in the group ranges from 514.43K to 25.03B. LVS holds the highest valuation in this group at 25.03B. The lowest valued company is CNDL at 514.43K.

High and low price notable news

The average weekly price growth across all stocks in the Hotels/Resorts/Cruiselines Industry was -1%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -3%. BALY experienced the highest price growth at 35%, while MSC experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Hotels/Resorts/Cruiselines Industry was 131%. For the same stocks of the Industry, the average monthly volume growth was 259% and the average quarterly volume growth was 55%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 56
P/E Growth Rating: 61
Price Growth Rating: 65
SMR Rating: 71
Profit Risk Rating: 90
Seasonality Score: -24 (-100 ... +100)
View a ticker or compare two or three
CZR
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

an operator of hotels and casinos

Industry HotelsResortsCruiselines

Industry
Casinos Or Gaming
Address
100 West Liberty Street
Phone
+1 775 328-0100
Employees
50000
Web
https://www.caesars.com
Interact to see
Advertisement
INSM shares are surging approximately +10% in premarket trading on Monday, March 23, 2026, from a prior close of $136.00, placing the premarket price near $149.60. The primary catalyst is the release of positive topline results from the Phase 3 ENCORE trial of ARIKAYCE® in patients with newly diagnosed or recurrent MAC (Mycobacterium avium complex) lung disease — a readout Insmed had flagged as expected in "March or April 2026".
CF shares are trading approximately -6% lower in Monday's premarket session, dropping from a Friday close of $124.90 to approximately $117.41. Primary catalyst: President Trump announced a five-day pause on strikes against Iranian energy infrastructure following "very good" diplomatic signals, triggering a sharp unwind of the geopolitical risk premium embedded in fertilizer stocks.
APGE shares surged approximately 16% in premarket trading on March 23, 2026, after the company announced positive 52-week data from Part A of its Phase 2 APEX clinical trial. The primary catalyst is a highly anticipated clinical readout showing that zumilokibart (APG777) delivered durable and deepening responses in patients with moderate-to-severe atopic dermatitis at both every 3-month and 6-month dosing intervals.
Shares of VALN are plummeting approximately 35% in Monday's session, from a Friday close of $10.66 to roughly $6.93, in heavy volume trading. The primary catalyst is the release of Phase 3 VALOR trial topline results for Valneva's Lyme disease vaccine candidate, co-developed with PFE (Pfizer) — results that showed strong clinical efficacy but failed to meet the pre-determined statistical criterion for the primary endpoint.
AXTI is surging approximately +11.00% in Monday's session, trading near $60.21, up from a prior closing price of $54.24. The move extends the stock's post-earnings rally that began last Thursday when shares jumped more than 19% following AXT's Q4 2025 results.
Tower Semiconductor (TSEM) shares are surging approximately +10% intraday on Monday, March 23, trading around $180, up from the previous close of $163.63 on March 20, 2026. The primary catalyst is the opening day of APEC 2026 in San Antonio, Texas, where Tower Semiconductor is presenting its newly unveiled Gen3 BCD power management platform designed to address escalating AI data center power demands.
CD is indicated down about 17% in premarket trading after the latest completed session, pointing to a sharp negative market reaction heading into the open. The stock’s weakness comes against a backdrop of lingering uncertainty following its privatization and delisting process from Nasdaq, which has left limited liquidity and a thinner news flow around the name.
SEDG is indicated down roughly 9% in premarket trading, following a strong advance in the prior regular session. The pullback comes after shares rallied on optimism around new product launches and an analyst upgrade, leaving the stock vulnerable to profit-taking and volatility.
NTGR shares surged approximately 11% in premarket trading on March 24, 2026, building on a roughly 20% overnight jump in the prior session. The primary catalyst is a landmark Federal Communications Commission (FCC) ruling that prohibits all imports of consumer routers manufactured overseas, citing national security concerns.
ANNA is surging approximately +20.00% in Tuesday's premarket session, rebounding sharply from Monday's -22.84% decline. The primary catalyst remains the ongoing U.S.-Iran military conflict, which disrupted Qatari LNG exports and drove European benchmark natural gas prices to multi-year highs.
Concentrix Corporation (CNXC) shares are falling approximately 11% in Tuesday's premarket session after the company released its fiscal Q1 2026 earnings report before market open. Adjusted diluted EPS came in at $2.61, missing the Wall Street consensus estimate of approximately $2.64.
Shares of Karyopharm Therapeutics (KPTI) are trading approximately 12% lower in Tuesday's premarket session, with the previous close at $7.63. The primary catalyst is the March 24 release of topline Phase 3 SENTRY trial data, in which the company met only one of two co-primary endpoints.
IBRX shares are down approximately 23% in Tuesday's session, trading near $7.24 after closing at $9.40 on Monday, March 23. The sharp decline follows an 11%+ surge in the prior session, with profit-taking and valuation pressure cited as primary triggers.
Shares of Circle Internet Group (CRCL) are down approximately 9% in Tuesday morning trading, extending a pullback from recent multi-month highs above $126. The primary catalyst appears to be a broad crypto-sector risk-off wave, with Bitcoin sliding below $69,000 and the Fear & Greed Index dropping to extreme fear territory.
ALM shares are indicated down about 11% in early Tuesday trading after closing the prior session at $16.93. The move comes after a powerful multi‑month rally that took the stock from below $3 to an intraday high of $22.55 earlier in March, leaving it vulnerable to profit-taking and volatility.​
LUNR shares are indicated down about 7% in Tuesday premarket trading after closing the last regular session at $20.31. The pullback follows a powerful rally driven by strong 2026 revenue guidance of $900 million–$1 billion and upbeat analyst commentary, including price target hikes and buy ratings.
MAZE shares are trading approximately 27% lower in premarket on March 25, 2026, after the company reported its highly anticipated Phase 2 HORIZON trial topline data for lead drug candidate MZE829. The catalyst is a dual announcement: Phase 2 clinical data for MZE829 in APOL1-mediated kidney disease (AMKD) alongside Q4 and full-year 2025 financial results.
ARM shares surged approximately +10% in premarket trading on March 25, 2026, hitting $148.6 from a prior close of approximately $135. The primary catalyst is Arm's historic strategic pivot: the company announced it will begin selling its own self-developed AGI CPU chips, breaking its decades-long "IP licensing only" business model.
Shares of Enliven Therapeutics (ELVN) are surging approximately +15% in premarket trading on March 25, 2026, driven by renewed investor enthusiasm around the company's advancing clinical program for ELVN-001 in chronic myeloid leukemia (CML). The stock's prior closing price on March 24, 2026 was $31.15, placing the premarket indicated price near $35.82.
AVXL shares are down approximately 29% in premarket trading on Wednesday, March 25, 2026, falling to roughly $2.97 from the prior close of $4.19. The primary catalyst is Anavex's formal withdrawal of its marketing authorization application (MAA) for blarcamesine from the European Union, announced in the early hours of March 25, 2026.